Saturday 17 October 2026
Export CANF’s income statement to Excel — free account
Can-Fite Biopharma Ltd
CANF Healthcare Biotechnology
Can-Fite Biopharma Ltd’s revenue for fiscal 2025 (year ended December 2025) was $405,000.00, down 39.9% from fiscal 2024.
1.76
0.09
−4.86%
Follow CANF
| Jun '26 | Jun '25 | Jun '24 | Sep '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | — | 291.00 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (30.78) | |
P/B ratio |
— | — | — | 43.09 | |
Price to Tangible BV |
— | — | — | 43.09 | |
EV/Sales |
— | — | — | 280.76 | |
EV/EBITDA |
— | — | — | 0.00 | |
EV/Operating CF |
— | — | — | (9.43) | |
EV/FCF |
— | — | — | (9.41) | |
Quick Ratio |
3.17 | 3.05 | 2.38 | 3.59 | |
Current Ratio |
3.60 | 3.60 | 2.93 | 4.10 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.07 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(1.00) | (0.04) | (4.00) | — | |
Interest Coverage |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 662.79% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 388.79% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
— | — | — | 0.02 | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (26.12%) | |
Free Cash Flow Yield |
— | — | — | (10.25%) | |
Revenue per Share |
— | — | — | 0.04 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
— | — | — | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(5.31) | (4.75) | (4.04) | — | |
Working Capital |
5.78 | 5.50 | 3.84 | 6.85 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | — | |
Net Current Asset Value |
4.80 | 4.09 | 2.39 | 5.13 | |
EV/EBIT |
— | — | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Payables |
1.29 | 1.86 | 1.49 | 1.43 | |
Average Assets |
9.52 | 10.60 | 7.60 | 10.91 | |
Average Common Equity |
5.85 | 6.34 | 3.48 | 6.32 |
Columns are period end dates